Researchers at Michigan Medicine have identified a mechanism by which sotagliflozin, an FDA-approved diabetes medication, reduces the risk of heart attack and stroke. Laboratory experiments revealed that the drug prevents excessive platelet activation, a process leading to dangerous blood clots. Sotagliflozin, a sodium-glucose cotransporter (SGLT) inhibitor, targets both SGLT1 and SGLT2 proteins, differing from primarily SGLT2 inhibitors like empagliflozin (Jardiance). Comparisons showed sotagliflozin limited platelet activation in blood samples, while empagliflozin had minimal effect. In mice with injured blood vessels, sotagliflozin reduced clot formation by approximately 60%, compared to 5-10% with empagliflozin. Researchers found that removing SGLT1 from platelets reduced clot formation by about 40%, but this did not fully replicate sotagliflozin’s effects. They hypothesize that SGLT1 in endothelial cells may also influence platelet interactions. The drug’s unique effect suggests additional mechanisms beyond SGLT1 inhibition may contribute to its anti-clotting properties. This research indicates sotagliflozin may offer protection against blood clots, potentially lowering the risk of heart attack and stroke. The drug is currently approved for use in adults with heart failure, type 2 diabetes, chronic kidney disease, and other cardiovascular risk factors.
Michigan Medicine study reveals how diabetes drug reduces stroke risk
For millions living with type 2 diabetes, heart disease remains one of the greatest threats to their health.
Recommended Medical News
All news →
Study discovers shared vocal patterns between birds and humans
McGill University researchers have identified "universal" vocal patterns across hundreds of bird species and found that many of the same patterns also appear in human song and speech from cultures around the world.
Curiox Biosystems strengthens commercial leadership to expand adoption of centrifuge-free sample preparation
Curiox Biosystems Inc (Curiox), a provider of centrifuge-free (C-FREE™) sample preparation technologies for reproducible, automated flow cytometry workflows, today announced the expansion of its senior commercial team and the formation of a Strategic Advisory Board (SAB).
ATCC selected by ARPA-H to support next-generation BioStabilization technologies
ATCC has been selected by the Advanced Research Projects Agency for Health (ARPA-H) as an affiliate to provide independent verification and validation (IV&V) for its BioStabilization Systems (BoSS) program.
Mutated neutrophils may trigger immune attacks in lupus
Scientists at La Jolla Institute for Immunology (LJI) and the University of Washington (UW) have discovered that patients with lupus have unusual mutations that may turn their bodies into battlegrounds.